Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc. (AQST)
Filing Type: Form 8-K (Current Report)
Date of Report: November 5, 2019
Reporting Period: This filing announces financial results for the three and nine months ended September 30, 2019, compared to the same periods in 2018.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed data. The filing text itself does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached Exhibit 99.1 for these figures.
Material Changes
The filing indicates a comparison between the 2019 and 2018 periods for the three and nine months ended September 30. However, the specific material changes in financial performance are not detailed in this text and are contained within the referenced press release.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release containing management's discussion of the results.
Legal Disclaimer: The information furnished under Item 2.02 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 5, 2019) for specific revenue, net loss, and cash position figures.
- Verify the specific year-over-year percentage changes for the three and nine-month periods ended September 30, 2019.
- Check for any updated forward-looking guidance or clinical trial milestones mentioned in the attached press release.
- Confirm the company's status as an "Emerging Growth Company" and any associated accounting election impacts.